Agenus Inc (AGEN) Stock Price, Quote & News

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGE...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 674 4400

Fax: 781 674 4200

Website: www.agenusbio.com

Address:

3 Forbes Road, Lexington, United States

pedmac2000 Jun. 20 at 7:23 PM

$AGEN is this like turning a cold tumor hot ? Seems dr Pat and Mink - Agenus could work together Will garo play well in the sand box ? https://www.facebook.com/share/v/1EWv4b3aaT/?mibextid=wwXIfr

0 · Reply

pedmac2000 Jun. 20 at 5:24 PM

$AGEN what ever happened to the work on qs21 Was it with Ginkgo Bioworks and SaponiQx ??

2 · Reply

bigred1414 Jun. 20 at 2:43 PM

$AGEN was the sp somehow manipulated last week so on Thursday (expiration date) the price would be under 3?

1 · Reply

JohnG8 Jun. 20 at 2:43 AM

$AGEN does anybody here Remember Peter the surgeon from Boise Idaho, who was living in San Diego? He was hot on bot/bal and would never say a bad word about Garo. Does anybody on this board think he was a plant? I used AI to try to determine if he was real, and the only person who could satisfy the criteria was a neurosurgeon. Does anybody know if Peter was a neurosurgeon? If he wasn’t, then I suspect Peter was a pumper, and he was really good at it.

8 · Reply

2_logs_higher Jun. 19 at 11:09 PM

$AGEN Annual share holder meeting G on 1st AA submission: We went in with immature data, oops sorry. G on 2nd AA submission: We went in with slightly better immature data, oops sorry. G on 3rd AA submission: it will be off until at least 2028.... Please be patient but not the patient. P3 read out is 2029, submission to FDA 2030? WS and AI have reduced Agen to a scratch off lottery ticket that guarantees monthly ATM dilution as well as absolutely needing another partner by Q1-2027. Who is in line behind Zydust?

1 · Reply

2_logs_higher Jun. 19 at 10:59 PM

$AGEN Summary on INCY buying AGEN Very interesting reading the stress test options. In the end, it says what to tell the CEO of Incy It is a hedge even at 1.2 billion in peak sales (Agen on CRC) only represents 45% of the JAK Patent Cliff in 2028 INCY stills need POVORCITINIB or additional M&A AGENUS alone doesn’t save incy from the jak patent Cliff, but it is the cheapest lottery ticket on the board It then goes on to say, do you want me to layer in financing dilution for Agenus if INCY doesn’t buy them The market (AI projections) already knows that it is the end of the road for AGEN

0 · Reply

2_logs_higher Jun. 19 at 10:39 PM

$AGEN 5 slides on why or at what value would incyte put on the valuation of acquiring agenus given their $4B in cash and 2028 patent cliff. Slide 1

2 · Reply

robbiekuss1 Jun. 19 at 3:14 PM

$AGEN | **Tom Harrison** | Healthcare marketing heavyweight. Chairman Emeritus of Diversified Agency Services (DAS), a division of Omnicom Group. Senior Operating Partner at Merida Capital. | **Independent Director** (Audit & Governance Chair) | | **Brian Corvese** | Investment fund management expert. Founder and President of Vencor Capital. Former portfolio manager at Chancellor Capital Management. | **Independent Director** (Compensation Chair) | | **Susan Hirsch** | Institutional investments specialist. Significant experience in compliance, affiliate transactions, and corporate financial oversight. | **Independent Director** | | **Jennifer Buell, Ph.D.** | Biotech executive. Current President and CEO of MiNK Therapeutics (an Agenus spin-off company specializing in cell therapies). | **Director** (Inside Board Member) | ### Key Takeaway on Board Ownership As noted previously, total individual insider ownership across all executives and board members sits right at about **1.5%**

2 · Reply

robbiekuss1 Jun. 19 at 3:13 PM

$AGEN The Board of Directors at Agenus Inc. consists of a mix of biotech executives, healthcare marketing veterans, and financial specialists. The primary members of the Agenus board, their main professional occupations, and their roles on the board include: ## Agenus Board of Directors & Occupations | Board Member | Primary Occupation / Professional Background | Board Role | | :--- | :--- | :--- | | **Garo H. Armen, Ph.D.** | Co-Founder of Agenus (1994). Former Wall Street analyst and investment banker at EF Hutton and Dean Witter Reynolds. | **Chairman & CEO** (Also serving as Interim CFO) | | **Timothy R. Wright** | Healthcare executive with decades of experience; former CEO of MiMedx and former President of the Americas for Elan Pharmaceuticals. | **Lead Independent Director** |

1 · Reply

joechuck71 Jun. 19 at 12:00 PM

$AGEN maybe some news next week ? 416k buy at the close is not a small number

3 · Reply

Agenus Transcript: AGM 2026

Jun 2, 2026, 4:30 PM EDT - 18 days ago

Agenus Announces Virtual 2026 Annual Shareholders Meeting

May 21, 2026, 5:00 PM EDT - 4 weeks ago

Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

$Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026$

May 21, 2026, 5:00 PM EDT - 4 weeks ago

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

2026-05-15T20:23:26.000Z - 5 weeks ago

Agenus announces publication of Phase 1b BOT+BAL data

May 15, 2026, 4:11 PM EDT - 5 weeks ago

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

May 13, 2026, 8:00 AM EDT - 5 weeks ago

Agenus Proxy statement: Proxy filing

2026-05-11T14:42:15.000Z - 5 weeks ago

Agenus reports Q1 revenue $33.7M vs. $24.1M last year

2026-05-11T14:38:34.000Z - 5 weeks ago

Agenus provides 2026 strategic priorities

2026-05-11T14:36:03.000Z - 5 weeks ago

Agenus announces conclusion of SEC investigation with no enforcement action

May 11, 2026, 9:30 AM EDT - 5 weeks ago

Agenus Earnings release: Q1 2026

May 11, 2026, 9:30 AM EDT - 5 weeks ago

Agenus Quarterly report: Q1 2026

May 11, 2026, 8:45 AM EDT - 5 weeks ago

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

May 4, 2026, 4:30 PM EDT - 6 weeks ago

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

Agenus Proxy statement: Proxy filing

Apr 21, 2026, 10:00 AM EDT - 2 months ago

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

2026-04-21T13:51:54.000Z - 2 months ago

Agenus appoints BAP Pharma as global partner for BOT+BAL access programs

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

Apr 20, 2026, 8:00 AM EDT - 2 months ago

Agenus Proxy statement: Proxy filing

2026-04-17T20:51:02.000Z - 2 months ago

Agenus reports Phase 2 results from BOT and BAL with agenT-797

$Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer$

Apr 17, 2026, 4:43 PM EDT - 2 months ago

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

$Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026$

Apr 3, 2026, 7:30 AM EDT - 2 months ago

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

2026-04-01T11:48:30.000Z - 2 months ago

Agenus announces first patient enrolled in Phase 3 BATTMAN trial of BOT+BAL

Apr 1, 2026, 7:30 AM EDT - 2 months ago

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

Mar 31, 2026, 4:30 PM EDT - 2 months ago

Agenus Transcript: AGM 2026

Mar 26, 2026, 4:52 PM EDT - 3 months ago

Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

Mar 17, 2026, 4:40 PM EDT - 3 months ago

Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer

Mar 16, 2026, 9:30 AM EDT - 3 months ago

Agenus Annual report: Q4 2025

Mar 16, 2026, 9:30 AM EDT - 3 months ago

Agenus Earnings release: Q4 2025

Mar 16, 2026, 7:30 AM EDT - 3 months ago

Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

2026-03-10T11:40:12.000Z - 3 months ago

Agenus triggers first $20M contingent payment under Zydus Lifesciences pact

Mar 10, 2026, 7:30 AM EDT - 3 months ago

Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs

Mar 4, 2026, 4:30 PM EST - 3 months ago

Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update

Feb 19, 2026, 3:15 PM EST - 4 months ago

Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL

Feb 9, 2026, 1:00 PM EST - 4 months ago

Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors

Jan 28, 2026, 4:00 PM EST - 5 months ago

Agenus Transcript: Status update

Jan 21, 2026, 7:30 AM EST - 5 months ago

Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab

Jan 20, 2026, 6:24 PM EST - 5 months ago

Agenus to Host First 2026 Stakeholder Webcast

Jan 15, 2026, 8:30 AM EST - 5 months ago

Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.

Jan 15, 2026, 7:01 AM EST - 5 months ago

Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness

Jan 12, 2026, 7:30 AM EST - 5 months ago

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

2025-12-29T22:10:27.000Z - 6 months ago

Agenus files to sell 1.32M shares of common stock or holders

2025-12-23T13:20:36.000Z - 6 months ago

Agenus publishes C-800-01 trial data in The Journal for ImmunoTherapy of Cancer

$Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC$

Dec 23, 2025, 8:05 AM EST - 6 months ago

Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC

Nov 19, 2025, 4:01 PM EST - 7 months ago

Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL

2025-11-18T14:36:16.000Z - 7 months ago

Agenus appoints Jose Iglesias as chief medical affairs officer

Nov 18, 2025, 8:41 AM EST - 7 months ago

Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC

Nov 10, 2025, 9:30 AM EST - 7 months ago

Agenus Quarterly report: Q3 2025

Nov 10, 2025, 9:30 AM EST - 7 months ago

Agenus Earnings release: Q3 2025

2025-11-10T13:05:24.000Z - 7 months ago

Agenus reports Q3 EPS $1.94, consensus $2.20

Nov 10, 2025, 7:30 AM EST - 7 months ago

Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

Nov 5, 2025, 1:47 PM EST - 8 months ago

Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report

Oct 21, 2025, 4:00 PM EDT - 8 months ago

Agenus Transcript: Status Update

2025-10-17T12:10:28.000Z - 8 months ago

Agenus announces new data from its BOT/BAL at ESMO 2025

$Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025$

Oct 17, 2025, 8:00 AM EDT - 8 months ago

Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025

Oct 16, 2025, 7:48 AM EDT - 8 months ago

Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights

Sep 9, 2025, 10:00 AM EDT - 10 months ago

Agenus Transcript: H.C. Wainwright 27th Annual Global Investment Conference

$France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer$

Sep 9, 2025, 7:43 AM EDT - 10 months ago

France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Sep 8, 2025, 7:00 AM EDT - 10 months ago

Agenus Slides: Corporate Presentation

Sep 5, 2025, 8:52 AM EDT - 10 months ago

Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 4:00 PM EDT - 10 months ago

Agenus Transcript: Stakeholder Briefing

Aug 26, 2025, 9:37 AM EDT - 10 months ago

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

Aug 19, 2025, 7:30 AM EDT - 10 months ago

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

Aug 11, 2025, 4:00 PM EDT - 11 months ago

Agenus Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 11 months ago

Agenus Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 11 months ago

Agenus Earnings release: Q2 2025

Aug 11, 2025, 7:30 AM EDT - 11 months ago

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

Jul 31, 2025, 7:30 AM EDT - 11 months ago

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

$Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025$

Jul 25, 2025, 12:46 PM EDT - 11 months ago

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

$Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3$

Jul 7, 2025, 8:55 AM EDT - 1 year ago

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

2025-06-17T11:40:18.000Z - 1 year ago

Agenus, Noetik announce research collaboration to develop predictive biomarkers

Jun 17, 2025, 7:30 AM EDT - 1 year ago

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Jun 10, 2025, 1:30 PM EDT - 1 year ago

Agenus Announces Virtual Annual Shareholders Meeting

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Agenus Proxy statement: Proxy Filing

2025-06-04T11:30:22.000Z - 1 year ago

Agenus price target raised to $6 from $4 at Baird

2025-06-04T10:10:31.000Z - 1 year ago

Agenus upgraded to Buy from Neutral at H.C. Wainwright

Jun 3, 2025, 4:30 PM EDT - 1 year ago

Agenus Transcript: Collaboration

Jun 3, 2025, 4:30 PM EDT - 1 year ago

Agenus Press release: Collaboration

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

May 30, 2025, 7:30 AM EDT - 1 year ago

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

May 15, 2025, 10:40 AM EDT - 1 year ago

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

May 12, 2025, 8:30 AM EDT - 1 year ago

Agenus Earnings Call Transcript: Q1 2025

May 12, 2025, 8:30 AM EDT - 1 year ago

Agenus Quarterly report: Q1 2025

May 12, 2025, 8:30 AM EDT - 1 year ago

Agenus Earnings release: Q1 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

Agenus Registration statement: Registration Filing

May 12, 2025, 7:30 AM EDT - 1 year ago

Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025, 7:20 AM EDT - 1 year ago

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

May 5, 2025, 8:00 AM EDT - 1 year ago

Agenus Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Agenus Proxy statement: Proxy Filing

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Apr 28, 2025, 3:30 PM EDT - 1 year ago

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Apr 25, 2025, 1:05 PM EDT - 1 year ago

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Apr 23, 2025, 12:05 PM EDT - 1 year ago

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Agenus Proxy statement: Proxy Filing

Mar 25, 2025, 4:40 PM EDT - 1 year ago

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

pedmac2000 Jun. 20 at 7:23 PM

$AGEN is this like turning a cold tumor hot ? Seems dr Pat and Mink - Agenus could work together Will garo play well in the sand box ? https://www.facebook.com/share/v/1EWv4b3aaT/?mibextid=wwXIfr

0 · Reply

pedmac2000 Jun. 20 at 5:24 PM

$AGEN what ever happened to the work on qs21 Was it with Ginkgo Bioworks and SaponiQx ??

2 · Reply

bigred1414 Jun. 20 at 2:43 PM

$AGEN was the sp somehow manipulated last week so on Thursday (expiration date) the price would be under 3?

1 · Reply

JohnG8 Jun. 20 at 2:43 AM

8 · Reply

2_logs_higher Jun. 19 at 11:09 PM

1 · Reply

2_logs_higher Jun. 19 at 10:59 PM

0 · Reply

2_logs_higher Jun. 19 at 10:39 PM

$AGEN 5 slides on why or at what value would incyte put on the valuation of acquiring agenus given their $4B in cash and 2028 patent cliff. Slide 1

2 · Reply

robbiekuss1 Jun. 19 at 3:14 PM

2 · Reply

robbiekuss1 Jun. 19 at 3:13 PM

1 · Reply

joechuck71 Jun. 19 at 12:00 PM

$AGEN maybe some news next week ? 416k buy at the close is not a small number

3 · Reply

Biotechguy21 Jun. 18 at 9:48 PM

$AGEN go back to the yahoo trash mb and take your losses to sir Garo 😂😂😂🤡🤡🤡

1 · Reply

neversurrender2024 Jun. 18 at 8:02 PM

$AGEN 416k buy @ $3 end of day,the crook is selling your company away for pennies on the dollar....damage is done...

1 · Reply

joechuck71 Jun. 18 at 8:01 PM

$AGEN intresting a buy 416,000 block at the close

1 · Reply

roomian53 Jun. 18 at 7:29 PM

$AGEN Sir Robert here. I listened to the Shareholders Meeting several times. When discussing reengaging with regulators he said they would make the case for approval "carefully, scientifically and with humility". It was the use of the word "humility" that caught my attention. What did he mean by using that word? Was he signalling a change in attitude from the "we will school the FDA" approach of the past?

5 · Reply

Biotechguy21 Jun. 18 at 6:41 PM

$AGEN the cfo approved it all 🤡🤡😂😂💰💰

0 · Reply

bigred1414 Jun. 18 at 5:34 PM

$AGEN how much of SH assets have been siphoned off to gman hobbies (his home country & suporting family on the job training (Zack) & personal travel expenses? Enough IS enough! Send email to Agenus addressed to independent board of director. They r required to forward your emails directly to that person!

2 · Reply

bigred1414 Jun. 18 at 5:28 PM

$AGEN instead of continuing ATM usage , gman can take out personal loans & pledge personal assets against the loan instead of pillaging SH. Also the board of directors should follow suite! The SH have pledged personal assets for many years with little to zero returns. No CFO is guarding the the Hen house!

0 · Reply

pedmac2000 Jun. 18 at 4:29 PM

$AGEN Possible treatment strategy An oncologist or researcher might envision: * MiNK iNKT cells infused into the patient. * ANKTIVA administered to stimulate and maintain those cells. * Possibly adding a checkpoint inhibitor such as Agenus’ botensilimab or balstilimab to remove immune suppression in the tumor microenvironment. That would attack cancer from three angles: * More immune cells (MiNK) * Stronger immune activation (IBRX/ANKTIVA) * Removal of tumor immune resistance (Agenus checkpoint inhibitors) Why investors talk about this Some biotech investors speculate that: * IBRX’s IL-15 platform could become a backbone for multiple cell therapies. * MiNK’s off-the-shelf iNKT cells may benefit from cytokine support such as IL-15. * Agenus’ checkpoint inhibitors could potentially be combined with either approach. However, this remains a scientific and investment thesis, not an established clinical program or partnership.

0 · Reply

Biotechguy21 Jun. 18 at 4:28 PM

$AGEN “stay tuned”

0 · Reply

Biotechguy21 Jun. 18 at 4:27 PM

$AGEN but they don’t. they have a ceo who has failed SHs for 30 years and he is also the cfo. complete pos stock

0 · Reply

FHLong Jun. 18 at 3:59 PM

$AGEN With a different and humble CEO and a new CFO, this company should have a $5 billion with a B market cap at this point. This is a disgrace.

1 · Reply

neversurrender2024 Jun. 18 at 3:26 PM

$AGEN if you are here for ten you might as well not even stick around..garo couldnt deliver ten even with a multiple of twenty... oh the goog ol days....

0 · Reply

Market Cap	124.93M
Revenue (ttm)	114.20M
Net Income (ttm)	120,000.00
EPS (ttm)	N/A
PE Ratio	1.17
Forward PE	150.00
Profit Margin	0.11%
Debt to Equity Ratio	-0.13

Volume	868,300
Avg Vol	871,666
Day's Range	N/A - N/A
Shares Out	41.64M
Stochastic %K	24%
Beta	1.57
Analysts	Strong Sell
Price Target	$15.50